Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

585 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer.
Sprooten J, Vankerckhoven A, Vanmeerbeek I, Borras DM, Berckmans Y, Wouters R, Laureano RS, Baert T, Boon L, Landolfo C, Testa AC, Fischerova D, Van Holsbeke C, Bourne T, Chiappa V, Froyman W, Schols D, Agostinis P, Timmerman D, Tejpar S, Vergote I, Coosemans A, Garg AD. Sprooten J, et al. Among authors: boon l. J Immunother Cancer. 2021 Nov;9(11):e003609. doi: 10.1136/jitc-2021-003609. J Immunother Cancer. 2021. PMID: 34795003 Free PMC article.
Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin.
Dudek-Perić AM, Ferreira GB, Muchowicz A, Wouters J, Prada N, Martin S, Kiviluoto S, Winiarska M, Boon L, Mathieu C, van den Oord J, Stas M, Gougeon ML, Golab J, Garg AD, Agostinis P. Dudek-Perić AM, et al. Among authors: boon l. Cancer Res. 2015 Apr 15;75(8):1603-14. doi: 10.1158/0008-5472.CAN-14-2089. Epub 2015 Mar 11. Cancer Res. 2015. PMID: 25762540
Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy.
Van Woensel M, Mathivet T, Wauthoz N, Rosière R, Garg AD, Agostinis P, Mathieu V, Kiss R, Lefranc F, Boon L, Belmans J, Van Gool SW, Gerhardt H, Amighi K, De Vleeschouwer S. Van Woensel M, et al. Among authors: boon l. Sci Rep. 2017 Apr 27;7(1):1217. doi: 10.1038/s41598-017-01279-1. Sci Rep. 2017. PMID: 28450700 Free PMC article.
Combining conventional therapy with immunotherapy: A risky business?
Coosemans A, Vankerckhoven A, Baert T, Boon L, Ruts H, Riva M, Blagden S, Delforge M, Concin N, Mirza MR, Ledermann JA, du Bois A, Vergote I. Coosemans A, et al. Among authors: boon l. Eur J Cancer. 2019 May;113:41-44. doi: 10.1016/j.ejca.2019.02.014. Epub 2019 Apr 6. Eur J Cancer. 2019. PMID: 30965214
Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy.
Van Damme H, Dombrecht B, Kiss M, Roose H, Allen E, Van Overmeire E, Kancheva D, Martens L, Murgaski A, Bardet PMR, Blancke G, Jans M, Bolli E, Martins MS, Elkrim Y, Dooley J, Boon L, Schwarze JK, Tacke F, Movahedi K, Vandamme N, Neyns B, Ocak S, Scheyltjens I, Vereecke L, Nana FA, Merchiers P, Laoui D, Van Ginderachter JA. Van Damme H, et al. Among authors: boon l. J Immunother Cancer. 2021 Feb;9(2):e001749. doi: 10.1136/jitc-2020-001749. J Immunother Cancer. 2021. PMID: 33589525 Free PMC article.
585 results